{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:32:04Z","timestamp":1789104724862,"version":"build-2803163510"},"reference-count":24,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"BC Cancer Foundation","award":["#FDN-148465"],"award-info":[{"award-number":["#FDN-148465"]}]},{"name":"BC Leadership Chair","award":["#FDN-148465"],"award-info":[{"award-number":["#FDN-148465"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Based on in vitro studies, it is known that androgen deprivation therapy (ADT) increases prostate-specific membrane antigen (PSMA) expression on prostate cancer (PCa) cells. However, ADT also has cytoreductive effects which can decrease lesion size. The present evaluation was conducted to further analyze the influence of ongoing ADT on [18F]DCFPyL positron emission tomography\/computed tomography (PET\/CT) performance in the setting of biochemically recurrent PCa. We retrospectively evaluated two groups of PCa patients, previously treated with radical intent, who had undergone [18F]DCFPyL PET\/CT because of biochemical relapse with a minimum PSA level of 0.4 ng\/mL. One group consisted of 95 patients under ADT at the time of the PET examination, and the other consisted of 445 patients not receiving ADT at the time of PET\/CT. The uptake characteristics of the cardiac blood pool, liver, parotid glands, and five most active lesions were measured and compared between these two groups. The overall detection rate of [18F]DCFPyL PET\/CT in patients under ADT at the time of imaging was significantly higher than patients not under ADT (91.6% vs. 80.4%, p-value = 0.007). However, the PSA-stratified differences in detection rates between patients with and without ADT did not reach statistical significance. Except for the maximal standardized uptake values corrected for lean body mass (SULmax) in the PSA range of 1 to &lt;2 ng\/mL, the intensity and volume of [18F]DCFPyL accumulation were higher in patients with ADT compared to the patients without. Statistical significance was attained for the SULmax in PSA range of 0.5 to &lt;1 ng\/mL (p-value = 0.0004) and metabolic tumor volume (MTV) in all PSA ranges (p-values of 0.0005 to 0.03). No significant difference was observed for radiotracer uptake in normal organs between the two groups with and without ADT. In this study population with biochemical recurrence of PCa and measurable PSA, ongoing ADT at the time of [18F]DCFPyL PET\/CT imaging was associated with higher radiotracer uptake and overall lesion detection rate. This could be due in part to the more aggressive disease phenotype in patients with ongoing ADT.<\/jats:p>","DOI":"10.3390\/diagnostics12092212","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T21:06:52Z","timestamp":1663103212000},"page":"2212","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["PSA-Stratified Performance of [18F]DCFPyL PET\/CT in Biochemically Recurrent Prostate Cancer Patients under Androgen Deprivation Therapy"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6196-6982","authenticated-orcid":false,"given":"Sara","family":"Harsini","sequence":"first","affiliation":[{"name":"BC Cancer Research Institute, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Wilson","sequence":"additional","affiliation":[{"name":"BC Cancer Research Institute, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada"},{"name":"Department of Radiology, University of British Columbia, Vancouver, BC V5Z 1M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"B\u00e9nard","sequence":"additional","affiliation":[{"name":"BC Cancer Research Institute, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada"},{"name":"Department of Radiology, University of British Columbia, Vancouver, BC V5Z 1M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.urology.2015.12.048","article-title":"The role PET with (68) gallium (Ga)-labelled prostate-specific membrane antigen (PSMA) in the Management of Patient with organ confined and locally advanced prostate cancer prior to radical treatment and after radical prostatectomy","volume":"95","author":"Rai","year":"2016","journal-title":"Urology"},{"key":"ref_2","first-page":"241","article-title":"Prostate-specific membrane antigen as a target for cancer imaging and therapy","volume":"59","author":"Kiess","year":"2015","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2967\/jnumed.119.226381","article-title":"A prospective study on 18F-DCFPyL PSMA PET\/CT imaging in biochemical recurrence of prostate cancer","volume":"60","author":"Rousseau","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2967\/jnumed.117.203877","article-title":"A perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies","volume":"59","author":"Bacich","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1084\/jem.20171052","article-title":"Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors","volume":"215","author":"Kaittanis","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s13139-016-0439-4","article-title":"Influence of androgen deprivation therapy on the uptake of PSMA-targeted agents: Emerging opportunities and challenges","volume":"51","author":"Bakht","year":"2017","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2967\/jnumed.116.181800","article-title":"68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: First human experience","volume":"58","author":"Hope","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","article-title":"Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy","volume":"48","author":"Wright","year":"1996","journal-title":"Urology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.euo.2018.03.010","article-title":"Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer","volume":"1","author":"Aggarwal","year":"2018","journal-title":"Eur. Urol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2967\/jnumed.118.223099","article-title":"Rapid modulation of PSMA expression by androgen deprivation: Serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade","volume":"60","author":"Emmett","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13550-016-0195-6","article-title":"Automated synthesis of [18 F] DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models","volume":"6","author":"Bouvet","year":"2016","journal-title":"EJNMMI Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e16007","DOI":"10.1200\/jco.2013.31.15_suppl.e16007","article-title":"Antiandrogen modulation of prostate-specific membrane antigen (PSMA): Dynamics and synergy with PSMA-targeted therapy","volume":"31","author":"DiPippo","year":"2013","journal-title":"Am. Soc. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/pros.22910","article-title":"Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer","volume":"75","author":"Murga","year":"2015","journal-title":"Prostate"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/pros.23522","article-title":"Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells","volume":"78","author":"Salemi","year":"2018","journal-title":"Prostate"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13550-015-0145-8","article-title":"Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy","volume":"5","author":"Meller","year":"2015","journal-title":"EJNMMI Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3892\/ijo.2012.1649","article-title":"Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells","volume":"41","author":"Liu","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1073\/pnas.1106383108","article-title":"Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen","volume":"108","author":"Evans","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of 68 Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: Evaluation in 1007 patients","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00259-017-3924-9","article-title":"PSA-stratified detection rates for [68 Ga] THP-PSMA, a novel probe for rapid kit-based 68 Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer","volume":"45","author":"Derlin","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s00259-018-4079-z","article-title":"Impact of long-term androgen deprivation therapy on PSMA ligand PET\/CT in patients with castration-sensitive prostate cancer","volume":"45","author":"Debus","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_22","first-page":"1357","article-title":"The Role of Castrate Status and Androgen Deprivation Therapy in PSMA-Based 18F-DCFPyL PET\/CT Imaging of Metastatic Prostate Cancer Patients","volume":"62","author":"Mena","year":"2021","journal-title":"Soc. Nucl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Vaz, S., Hadaschik, B., Gabriel, M., Herrmann, K., Eiber, M., Costa, D.J.E.J.o.N.M., and Imaging, M. (2020). Influence of Androgen Deprivation Therapy on PSMA Expression and PSMA-Ligand PET Imaging of Prostate Cancer Patients, Springer.","DOI":"10.1007\/s00259-019-04529-8"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00259-019-04635-7","article-title":"Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68 Ga-PSMA-11 PET\/MRI in men with treatment-na\u00efve prostate cancer","volume":"47","author":"Ettala","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/9\/2212\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:30:19Z","timestamp":1760142619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/9\/2212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["diagnostics12092212"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics12092212","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]}}}